Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of over 15 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2018a 2019e 2020e 2021e  2022e  2023e  2024e
Core Products              
Cimzia 1,446 1,549 1,580 1,598 1,584 1,536 1,436
Vimpat 1,099 1,250 1,349 1,439 1,274 860 657
Keppra  790 749 714 653 606 567 542
Briviact 142 223 293 366 425 480 521
Neupro 321 329 328 288 231 197 158
6 Potential new Product Launches*
(global sales, non-risk adj.)
             
Evenity (romosozumab) 40   108  198  288 374   466
Midazolam nasal spray 8 23  45  65  84  98 
Bimekizumab 59  175  323   471
Rozanolixizumab (Rozimab/Roza) 10   42 115  206 
Padsevonil 33  80   128
Anti-Tau  0  0  0  25  63

  *in the next 5 years

UCB FY Consensus Earnings Estimates (Average)

In € million 2018a 2019e 2020e 2021e 
Net Sales  4,412 4,531 4,761  4,935 
Revenue  4,632 4,724 4,941 5,112
Recurring EBIT 1,105  1,049 1,153 1,281
Recurring EBITDA 1,398  1,327 1,440 1,569
Net Profit*  800 775 856 968
Core EPS (€) 4.78  4.63 5.07 5.68

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2018a 2019e 2020e 2021e  2022e  2023e  2024e
Core Products              
Cimzia 1,446 1,553 1,576 1,610 1,621 1,598 1,446
Vimpat 1,099 1,251 1,341 1,427 1,238 820 690
Keppra 790 742 710 650 601 560 532
Briviact 142 222 300 378 430 474 536
Neupro 321 327 326 280 220 183 159
6 Potential new Product Launches*
(global sales, non-risk adj.)
             
Evenity (romosozumab)  40 100  181  286  355 438 
Midazolam nasal spray 20  40  65   80 96 
Bimekizumab  0 50  150  300  432 
Rozanolixizumab (Rozimab/Roza)  0 12  105  146
Padsevonil 22   68  108
Anti-Tau  0  0

 *in the next 5 years

UCB FY Consensus Earnings Estimates (Median)

In € million 2018a 2019e 2020e 2021e 
Net Sales  4,412 4,520 4,734  4,947 
Revenue  4,632 4,725 4,921 5,134
Recurring EBIT 1,105  1,044 1,150 1,288
Recurring EBITDA  1,398 1,334 1,430 1,568
Net Profit*  800  757 841 964
Core EPS (€)  4.78 4.64 5.08 5.70

*attributable to UCB shareholders

Downloads:
UCB FY 2019 Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 16 September, 2019



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.